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ABSTRACT 
Stopped-flow kinetic investigation of reduction of Fe
(III)
-maltol complex is reported. The rates are dependent on pH in a 
complex way. On one hand at low pH there is a predominance of Fe
(III)
(maltol)2 which is easier to reduce compared to 
Fe
(III)
 (maltol)3 which is more resistant to reduction. On the other hand ascorbate is a stronger reducing agent at higher pH. 
The rates are also found to be inversely dependent on the concentration of free ligand. These observations are explained 
by the following rate law:  
Rate = ((k0 +k1[H
+
])k2 [Asc
-
]/ (k-1[HMal] + k2[Asc
-
])) + k3 [Asc
-
] ) [Fe
III
(Mal)3] 
 Here k1 is the rate constant for acid hydrolysis of the Fe(maltol)3 complex to Fe(maltol)2 complex and is directly controlled 
by H
+
, k0 is the rate constant for hydrolysis of the Fe(maltol)3 complex to Fe(maltol)2 complex and is an intrinsic process, k-
1 is the rate constant of reformation of the tris complex by reaction of the bis complex and the free ligand, k2 is the rate 
constant for reduction of the bis complex by ascorbate and k3 is the rate constant for the reduction of the tris complex by 
ascorbate. 
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INTRODUCTION: 
MALTOL (3-hydroxy-2-Methyl pyran-4-one, CAS No. 118-71-8) is similar to ring C of flavonols which are a class of 
flavanoids having a 3-hydroxy-2-phenylchromen-4-one backbone [1].  Flavanoids in general and flavanols in particular 
have strong antioxidant properties [2]. In many cases, the antioxidant properties are attributed to the 3-hydroxy-4-one 
functionality which makes it a very strong Fe(III) chelator and an inhibitor of Fenton reaction [3]. The Fe(III) chelating 
property of Maltol (Structures given in figure 1) has characteristics similar to that of many flavanols [4]. Metal chelation 
involves deprotonation of the 3-hydroxy group and thus 3:1 complexes with trivalent metal ions (Fe
3+
, Al
3+
, Ga
2+
 etc.) and 
2:1 complexes with divalent metal ions (Cu
2+
, VO
2+
, Zn
2+
 etc.) are neutral [5]. Complexes of maltol have been suggested 
for use as medicinal agents, e.g. Bis Maltol OxoVanadium (BMOV) in treatment of diabetes and as nutritional supplements 
[6]. It has a very low toxicity profile and has been used in food industry for a long time [7]. However there has been some 
apprehension about its excessive use because of its possible role in Aluminum neurotoxicity [8]. 
In view of its potential use as an insulin mimicking agent, the vanadium complex of maltol has been studied for its redox 
reactivity [9]. It has been suggested that iron-maltol complex is first dissociated and the metal and the ligand are 
metabolized separately after this dissociation [10]. In this study, we report the kinetics of reduction Fe(III) complex of 
maltol by ascorbate at different pH. The reactions were carried out at constant temperature and ionic strength while 
Fe:Maltol ratio, pH and Ascorbate concentrations were varied. The data is explained in terms of (i) Equilibrium between 
tris and bis forms of the complex; (ii) Varying reduction rates for the bis and tris complexes at different pH resulting from 
changing redox potentials of the bis and tris complexes and of ascorbate. 
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Figure 1 
MATERIALS AND METHODS 
Fe(III) maltol complexes were prepared by mixing appropriate concentrations of Fe(III) and the ligand and making up the 
volume in a desired buffer (formate or acetate). Solutions were purged with oxygen free Nitrogen before introducing them 
into storage and drive syringes of the stopped-flow instrument. 
Sodium ascorbate was dissolved in the buffer of chosen pH and the working solutions were prepared from a stock solution 
whose concentration was estimated by measuring the reducing equivalents present as indicated by its reaction with 
K3[Fe(CN)6]. The buffer solutions used for preparation of stock and working solutions, too, were purged with oxygen free 
nitrogen. 
The stopped-flow reduction experiments were carried out using an Applied Photophysics Rapid Mixing Accessory whose 
cuvet was placed in a spectrometer. The output of the spectrometer was fed into a computer through an A/D converter. 
Files of time versus voltages (which were subsequently calibrated to give absorbance values) were created for each 
reaction [11]. 
A series of kinetic runs were carried out at a fixed temperature, pH and ionic strength varying the ascorbate concentrations 
which were in pseudo first order excess over the Fe(III)-maltol complexes. In different series the pH of the reactions was 
changed. 
RESULTS AND DISCUSSION 
Kinetic results are shown in the table 1 and Figures 2 & 3. The following trends are noticeable: 
*At low pH (3.0-4.5), plots of kobs versus [Ascorbate] are indicative of (nearly) saturation kinetics. However, as 
ascorbate concentration is increased further, there is a small but continuing increase in kobs. 
 
*The observed rate constants decrease as the ratio of maltol concentration to the Fe concentration is increased. 
 
*In the lower pH range the rates increase with increasing [H
+
], however in the higher pH range rates increase as 
the pH is increased. 
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Figure 2:  Reduction of Fe(III)-Maltol Complex with Ascorbate at Different Ratios of Maltol 
I S S N  2 3 2 1 - 8 0 7 X  
V o l u m e  1 2  N u m b e r 4  
J o u r n a l  o f  A d v a n c e s  i n  C h e m i s t r y  
4340 | P a g e                                   c o u n c i l  f o r  I n n o v a t i v e  R e s e a r c h  
F e b r u a r y  2 0 1 6                                              w w w . c i r w o r l d . c o m  
[AA]        M
0.00 0.01 0.02 0.03 0.04 0.05 0.06
k o
bs
   
  s
-1
0.0
0.5
1.0
1.5
2.0
[AA]    M vs pH 3 
[AA]    M vs pH 3 calc 
[AA]    M vs pH 4 
[AA]    M vs pH 4 calc 
[AA]    M vs pH 5 
[AA]    M vs pH 5 calc 
[AA]    M vs pH6 
[AA]    M vs pH 6 calc 
 
Figure 3: Comparison of the Calculated and Experimental Rate Constants for the Reduction of Fe(III)-Maltol 
Complex by Ascorbate at Different pH 
TABLE 1 
Rate parameters for Reduction of Ferric Maltol Complex by Ascorbate at Different pH 
[Fe(Maltol)3] =1.00 x 10
-4
 M, T = 25
o
 C, I = 0.35 M 
k1 = 2x10
5
 M
-1
s
-1 
(estimated from graphs) 
k-1 = 5x10
4
 M
-1
s
-1
 
pH   k2   k3 
x10
-3
 M
-1
s
-1
  M
-1
s
-1
 
3.00   8.2   4.5 
4.00   6.6   17.8 
5.00   2.5   18.4 
6.00   1.00   27.2 
To explain these observations, the following mechanism is suggested: 
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This mechanism will yield a two term rate law. The first term would correspond to the reduction of  Fe
III
(Mal)2(H2O)2
+
. The 
concentration of this species would increase as the pH decreases and as a result the observed rate constant will also 
increase as the pH is lowered. Another requirement of this mechanism would be that the first term, corresponding to the 
reduction of Fe
III
(Mal)2(H2O)2
+
 , would have an inverse dependence upon excess free Maltol. Thus using steady-state 
approximation for the concentration of Fe
III
(Mal)2(H2O)2
+
 , the first term of the overall rate law would be equal to: 
 Rate = (k1k2[H
+
] [Asc
-
] (k-1[HMal] + k2[Asc
-
])
-1
) [Fe
III
(Mal)3] 
Figure 2 shows the effect of [Hmal] on the observed rate constant which decreases as the concentration of free Maltol is 
increased. If this was the only term in the rate equation, then we would expect at high ascorbate concentrations, the 
observed rate constants (at any given pH) would level off, i.e., increasing ascorbate further would not increase kobs any 
more. This expectation is not met. We suggest that the reason for this is that  Fe
III
(Mal)2(H2O)2
+
 is not the only species 
being reduced. Particularly, at higher pH, Fe
III
(Mal)3 is present in larger proportion and at the same time, Ascorbate is a 
stronger reducing agent. So, the introduction of a second term in the rate law is warranted. This would be: 
 Rate = k3 [Asc
-
] [Fe
III
(Mal)3]  
The overall rate equation, thus, becomes: 
 Rate = ((k1k2[H
+
] [Asc
-
] (k-1[HMal] + k2[Asc
-
])
-1
) + k3 [Asc
-
] ) [Fe
III
(Mal)3] 
In a given kinetic run, when [H
+
] is kept constant with the use of a buffered medium, a known constant excess of maltol is 
kept and [Asc
-
] is in large excess over the Fe(III) complex to maintain pseudo first order conditions, the rate equation is 
simplified as: 
 Rate = kobs [Fe
III
(Mal)3]  where, 
 kobs = (k1k2[H
+
] /(k-1[HMal] + k2[Asc
-
])) + k3 )[Asc] ) 
Plots of kobs vs. [Asc
-
] were subjected to non-linear least square analysis after approximation of k1[H
+
] and calculating k-1 
values from the literature values of the formation constants and our approximate values of k1. It is to be understood that 
both the values of k2 as well as of k3 will change as pH changes. The values of different rate constants obtained in this 
manner are given in Table 1.  
CONCLUSION 
Since Iron maltol complex has been suggested as a useful agent for Iron deficiency anemia patients who are intolerant of 
iron
12,13
, it is useful to understand how iron is released from this complex at different pH (low pH as in stomach or higher 
pH as in small intestine) in presence of ascorbic acid which is usually administered along with iron supplements. 
Reduction of Ferric-maltol complex is more rapid at lower pH. If the release of free iron is desired to be avoided till the 
complex reaches the small intestine, it would be better to delay the administration of ascorbic acid for a reasonable 
interval after the ferric maltol supplement is give.   
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